Landscape of genetic variants in sporadic meningiomas captured with clinical genomics

Acta Neurochir (Wien). 2022 Sep;164(9):2491-2503. doi: 10.1007/s00701-022-05316-5. Epub 2022 Jul 26.


Background: Meningiomas are the most common primary central nervous system tumor. Previous studies have characterized recurrent genetic alterations that can predict patient prognosis and potentially provide new avenues for therapeutic intervention. Continued efforts to characterize the genomic changes in meningioma samples can aid in the discovery of therapeutic targets and appropriate patient stratification.

Methods: We performed targeted genomic sequencing on 25 primary and 2 recurrent meningiomas using a 500-gene panel, including canonical meningioma drivers. We further detail the genomic profiles and relevant clinical findings in three cases of angiomatous meningiomas and two recurrent atypical meningiomas.

Results: Our approach uncovers a diverse landscape of genomic variants in meningioma samples including mutations in established meningioma-related genes NF2, AKT1, PIK3CA, and TRAF7. In addition to known meningioma drivers, we uncover variants in genes encoding other PI3K subunits, Notch/hedgehog/Wnt signaling pathway components, and chromatin regulators. We additionally identify 22 genes mutated across multiple samples. Three patients included in the study were diagnosed with angiomatous WHO grade I meningiomas, all three of which contained variants in the PI3K-AKT signaling pathway previously described to regulate tumor angiogenesis. Analysis of patient-matched primary and recurrent atypical meningiomas revealed clonal enrichment for mutations in the SWI/SNF complex subunits ARID1A and SMARCA4.

Conclusions: Targeted genomics implemented in neuro-oncology care can enhance our understanding of the genetic underpinnings of central nervous system tumors, including meningiomas. These molecular signatures may be clinically useful in dictating treatment strategies and patient follow-up.

Keywords: Atypical meningioma; Genetics; Genomics; Meningioma; Targeted therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Helicases
  • Genomics
  • Humans
  • Meningeal Neoplasms* / pathology
  • Meningioma* / pathology
  • Neoplasm Recurrence, Local
  • Nuclear Proteins
  • Phosphatidylinositol 3-Kinases / genetics
  • Transcription Factors


  • Nuclear Proteins
  • Transcription Factors
  • SMARCA4 protein, human
  • DNA Helicases